Involvement of the tage-rage system in non-alcoholic steatohepatitis: Novel treatment strategies

World Journal of Hepatology

Volumn 6, Issue 12, 2014, Pages 880-893

  Takeuchi, Masayoshi ^a   Takino, Jun Ichi ^b   Sakasai Sakai, Akiko ^a   Takata, Takanobu ^a   Ueda, Tadashi ^a   Tsutsumi, Mikihiro ^a   Hyogo, Hideyuki ^c   Yamagishi, Sho Ichi ^d  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Cardiovascular disease; Diabetes mellitus; Dietary advanced glycation end products; Dietary fructose; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Receptor for advanced glycation end products; Toxic advanced glycation end products; Toxic advanced glycation end products receptor for advanced glycation end products system

Indexed keywords

EID: 84987917076     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i12.880     Document Type: Article

References (127)

1. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317 [PMID: 19065650 DOI: 10.1002/hep.22603]
2. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719 [PMID: 7489979 DOI: 10.1002/ hep.1840220616]
3. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755 [PMID: 15082596 DOI: 10.1136/ gut.2003.019984]
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 [PMID: 10348825 DOI: 10.1016/S0016- 5085(99) 70506-8]
5. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379 [PMID: 11826411 DOI: 10.1053/jhep.2002.30692]
6. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850 [PMID: 11473047 DOI: 10.2337/diabetes.50.8.1844]
7. Hyogo H, Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008; 14: 969-972 [PMID: 18473847 DOI: 10.2174/1381612 08784139701]
8. Hyogo H, Chayama K, Yamagishi S. Nonalcoholic fatty liver disease and cardiovascular disease. Curr Pharm Des 2014; 20: 2403-2411 [PMID: 23844815 DOI: 10.2174/1381612811319999 0476]
9. Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 2014; 20: 8407-8415 [PMID: 25024598 DOI: 10.3748/wjg.v20.i26.8407]
10. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299 [PMID: 16022668 DOI: 10.2174/1381612054367300]
11. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 2003; 23: 129-134 [PMID: 15224502]
12. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 63-79 [PMID: 14568010 DOI: 10.1016/j.abb.2003.08.009]
13. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101 [PMID: 11905595 DOI: 10.1046/j.1365-2796.2002.00932.x]
14. Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002; 4: 228-237 [PMID: 11931721 DOI: 10.1007/s11883-002-0024-4]
15. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000; 2: 430-436 [PMID: 11122775 DOI: 10.1007/s11883-000-0082-4]
16. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006; 3: 73-77 [PMID: 16472128 DOI: 10.2174/1567202067755 41804]
17. Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses 2004; 63: 449-452 [PMID: 15288366 DOI: 10.1016/j.mehy.2004.02.042]
18. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 2006; 6: 351-358 [PMID: 16712480 DOI: 10.2174 /156652406776894536]
19. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis 2009; 16: 845-858 [PMID: 19387117 DOI: 10.3233/JAD-2009-0974]
20. Takeuchi M, Takino J, Yamagishi S. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Curr Drug Targets 2010; 11: 1468-1482 [PMID: 20583971 DOI: 10.2174/1389450111009011468]
21. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006; 49: 3094-3099 [PMID: 17004092 DOI: 10.1007/ s00125-006-0437-7]
22. Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, Chayama K. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 2008; 43: 298-304 [PMID: 18458846 DOI: 10.1007/s00535-007-2152-7]
23. Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nonaka M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma S. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 1112-1119 [PMID: 17559366 DOI: 10.1111/j.1440-1746.2007.04943.x]
24. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34 [PMID: 1540533 DOI: 10.1016/S1054- 358 9(08)60961-8]
25. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-151 [PMID: 8139257]
26. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234 [PMID: 7598459 DOI: 10.1146/annurev.med.46.1.223]
27. Takeuchi M, Makita Z. Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr Mol Med 2001; 1: 305-315 [PMID: 11899079 DOI: 10.2174/1566524013363735]
28. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321 [PMID: 3283558 DOI: 10.1056/NEJM198805193182007]
29. Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981; 211: 491-493 [PMID: 6779377 DOI: 10.1126/science.6779377]
30. Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 1981; 213: 222-224 [PMID: 12192669 DOI: 10.1126/science.12192669]
31. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996; 97: 1422-1428 [PMID: 8617874 DOI: 10.1172/JCI118563]
32. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110-117 [PMID: 8040253 DOI: 10.1172/JCI117296]
33. Poulsen MW, Hedegaard RV, Andersen JM, de Courten B, Bügel S, Nielsen J, Skibsted LH, Dragsted LO. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol 2013; 60: 10-37 [PMID: 23867544 DOI: 10.1016/ j.fct.2013.06.052]
34. Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med 1999; 5: 393-405 [PMID: 10415164]
35. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000; 6: 114-125 [PMID: 10859028]
36. Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita Z. Immunological detection of a novel advanced glycation end-product. Mol Med 2001; 7: 783-791 [PMID: 11788793]
37. Takeuchi M, Iwaki M, Takino J, Shirai H, Kawakami M, Bucala R, Yamagishi S. Immunological detection of fructose-derived advanced glycation end-products. Lab Invest 2010; 90: 1117-1127 [PMID: 20212455 DOI: 10.1038/labinvest.2010.62]
38. Takeuchi M, Yamagishi S. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med Hypotheses 2004; 63: 453-455 [PMID: 15288367 DOI: 10.1016/ j.mehy.2004.03.005]
39. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002; 50: 325-392 [PMID: 12198816]
40. Maekawa K, Tanimoto T, Okada S. Gene expression of enzymes comprising the polyol pathway in various rat tissues determined by the competitive RT-PCR method. Jpn J Pharmacol 2002; 88: 123-126 [PMID: 11855672 DOI: 10.1254/ jjp.88.123]
41. Iwata T, Popescu NC, Zimonjic DB, Karlsson C, Höög JO, Vaca G, Rodriguez IR, Carper D. Structural organization of the human sorbitol dehydrogenase gene (SORD). Genomics 1995; 26: 55-62 [PMID: 7782086 DOI: 10.1016/0888-7543(95)8 0082-W]
42. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21-33 [PMID: 9549756]
43. Schalkwijk CG, Stehouwer CD, van Hinsbergh VW. Fructose- mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev 2004; 20: 369-382 [PMID: 15343583 DOI: 10.1002/dmrr.488]
44. Gaby AR. Adverse effects of dietary fructose. Altern Med Rev 2005; 10: 294-306 [PMID: 16366738]
45. Hallfrisch J. Metabolic effects of dietary fructose. FASEB J 1990; 4: 2652-2660 [PMID: 2189777]
46. Mayes PA. Intermediary metabolism of fructose. Am J Clin Nutr 1993; 58: 754S-765S [PMID: 8213607]
47. James J, Thomas P, Cavan D, Kerr D. Preventing childhood obesity by reducing consumption of carbonated drinks: cluster randomised controlled trial. BMJ 2004; 328: 1237 [PMID: 15107313 DOI: 10.1136/bmj.38077.458438.EE]
48. Teff KL, Elliott SS, Tschöp M, Kieffer TJ, Rader D, Heiman M, Townsend RR, Keim NL, D'Alessio D, Havel PJ. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 2004; 89: 2963-2972 [PMID: 15181085]
49. Faeh D, Minehira K, Schwarz JM, Periasamy R, Park S, Tappy L. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 2005; 54: 1907-1913 [PMID: 15983189]
50. Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 2579-2588 [PMID: 20518077 DOI: 10.3748/wjg.v16.i21.2579]
51. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010; 7: 251-264 [PMID: 20368739 DOI: 10.1038/nrgastro.2010.41]
52. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012; 23: 203-208 [PMID: 22129639 DOI: 10.1016/ j.jnutbio.2011.09.006]
53. Yilmaz Y. Review article: fructose in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35: 1135-1144 [PMID: 22469071 DOI: 10.1111/j.1365-2036.2012.05080.x]
54. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013; 57: 2525-2531 [PMID: 23390127 DOI: 10.1002/hep.26299]
55. Pollock NK, Bundy V, Kanto W, Davis CL, Bernard PJ, Zhu H, Gutin B, Dong Y. Greater fructose consumption is associated with cardiometabolic risk markers and visceral adiposity in adolescents. J Nutr 2012; 142: 251-257 [PMID: 22190023 DOI: 10.3945/jn.111.150219]
56. Lê KA, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, Boesch C, Ravussin E, Tappy L. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am J Clin Nutr 2006; 84: 1374-1379 [PMID: 17158419]
57. Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19: 1166-1172 [PMID: 23482247 DOI: 10.3748/wjg.v19.i8.1166]
58. Kargulewicz A, Stankowiak-Kulpa H, Grzymislawski M. Dietary recommendations for patients with nonalcoholic fatty liver disease. Prz Gastroenterol 2014; 9: 18-23 [PMID: 24868294 DOI: 10.5114/pg.2014.40845]
59. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-691 [PMID: 8751438]
60. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498: 99-111 [PMID: 11108954]
61. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, Schmidt AM. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002; 59: 1117-1128 [PMID: 12222959]
62. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D'Agati V, Schmidt AM. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 2003; 419: 80-88 [PMID: 14568011 DOI: 10.1016/j.abb.2003.08.030]
63. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15: 16R-28R [PMID: 15764591]
64. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996; 93: 11047-11052 [PMID: 8855306]
65. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1: 634-646 [PMID: 8529130]
66. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, Takahashi K, Shichiri M, Horiuchi S. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995; 230: 408-415 [PMID: 7607209]
67. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, Nakayama H. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci 2001; 947: 350-355 [PMID: 11795289]
68. Ohgami N, Nagai R, Ikemoto M, Arai H, Miyazaki A, Hakamata H, Horiuchi S, Nakayama H. CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications 2002; 16: 56-59 [PMID: 11872368]
69. Ohgami N, Nagai R, Miyazaki A, Ikemoto M, Arai H, Horiuchi S, Nakayama H. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 2001; 276: 13348-13355 [PMID: 11278947 DOI: 10.1074/jbc.M011613200]
70. Jono T, Miyazaki A, Nagai R, Sawamura T, Kitamura T, Horiuchi S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 2002; 511: 170-174 [PMID: 11821070]
71. Tamura Y, Adachi H, Osuga J, Ohashi K, Yahagi N, Sekiya M, Okazaki H, Tomita S, Iizuka Y, Shimano H, Nagai R, Kimura S, Tsujimoto M, Ishibashi S. FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem 2003; 278: 12613-12617 [PMID: 12473645 DOI: 10.1074/jbc. M210211200]
72. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-443 [PMID: 11757079 DOI: 10.1002/dmrr/233]
73. Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 2005; 25: 879-882 [PMID: 15863717 DOI: 10.1161/01.ATV.0000164804.05324.8b]
74. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-1109 [PMID: 12495433]
75. Yamamoto Y, Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi A, Takeuchi M, Yamamoto H. Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 2007; 77 Suppl 1: S30-S40 [PMID: 17462779]
76. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Ueno T, Sata M. Pigment epitheliumderived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett 2006; 580: 2788-2796 [PMID: 16674952 DOI: 10.1016/j. febset. 2006.04.050]
77. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M. Pigment epithelium- derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm Metab Res 2008; 40: 620-625 [PMID: 18792873 DOI: 10.1055/s-0028-1083785]
78. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007; 131: 1728-1734 [PMID: 17979495]
79. Takino J, Kobayashi Y, Takeuchi M. The formation of intracellular glyceraldehyde-derived advanced glycation endproducts and cytotoxicity. J Gastroenterol 2010; 45: 646-655 [PMID: 20084527 DOI: 10.1007/s00535-009-0193-9]
80. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-443 [PMID: 12891546 DOI: 10.1016/S0016-5085(03)00907-7]
81. Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-1717 [PMID: 15330907 DOI: 10.1111/j.1572-0241.2004.40009.x]
82. Hamelin M, Mary J, Vostry M, Friguet B, Bakala H. Glycation damage targets glutamate dehydrogenase in the rat liver mitochondrial matrix during aging. FEBS J 2007; 274: 5949-5961 [PMID: 17949437 DOI: 10.1111/j. 1742-4658.2007.06 118.x]
83. Kumar PA, Kumar MS, Reddy GB. Effect of glycation on alpha- crystallin structure and chaperone-like function. Biochem J 2007; 408: 251-258 [PMID: 17696877 DOI: 10.1042/BJ20070989]
84. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 573-582 [PMID: 17653654 DOI: 10.1007/ s00535-007-2060-x]
85. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008; 16: 1394-1399 [PMID: 18369343 DOI: 10.1038/oby.2008.64]
86. Chiang CH, Huang PH, Chung FP, Chen ZY, Leu HB, Huang CC, Wu TC, Chen JW, Lin SJ. Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease. PLoS One 2012; 7: e31799 [PMID: 22359630 DOI: 10.1371/journal.pone.0031799]
87. Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N, Mizoguchi M, Imaizumi T. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 2012; 30: 42-48 [PMID: 20626403 DOI: 10.1111/j. 1755-592 2.2010.00177.x]
88. Tsunosue M, Mashiko N, Ohta Y, Matsuo Y, Ueda K, Ninomiya M, Tanaka S, Hoshiko M, Yoshiyama Y, Takeuchi M, Ueda S, Yamagishi S. An alpha-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehydederived advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2010; 10: 139-141 [PMID: 19834782 DOI: 10.1007/s10238-009-0074-9]
89. Tahara N, Yamagishi S, Takeuchi M, Honda A, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, Ishibashi M, Hayabuchi N, Matsui T, Imaizumi T. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care 2012; 35: 2618-2625 [PMID: 22912424 DOI: 10.2337/dc12-0087]
90. Ueda S, Yamagishi S, Matsui T, Noda Y, Ueda S, Jinnouchi Y, Sasaki K, Takeuchi M, Imaizumi T. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther 2012; 30: 249-254 [PMID: 21884000 DOI: 10.1111/j.1755-5922.2011.00264.x]
91. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S, Takeuchi M, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Matsuzaki M. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol 2013; 12: 5 [PMID: 23289728 DOI: 10.1186/1475-2840-12-5]
92. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014; 59: 1174-1197 [PMID: 24002776 DOI: 10.1002/hep. 26717]
93. Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab 2009; 10: 159-163 [PMID: 19275550]
94. Kitahara Y, Takeuchi M, Miura K, Mine T, Matsui T, Yamagishi S. Glyceraldehyde-derived advanced glycation end products (AGEs). A novel biomarker of postprandial hyperglycaemia in diabetic rats. Clin Exp Med 2008; 8: 175-177 [PMID: 18791692 DOI: 10.1007/s10238-008-0176-9]
95. Ekong U, Zeng S, Dun H, Feirt N, Guo J, Ippagunta N, Guarrera JV, Lu Y, Weinberg A, Qu W, Ramasamy R, Schmidt AM, Emond JC. Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol 2006; 21: 682-688 [PMID: 16677153]
96. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U, Dun H, Lu Y, Qu W, Schmidt AM, Emond JC. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004; 39: 422-432 [PMID: 14767995]
97. Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H, Qu W, Lu Y, Rong LL, Hofmann MA, Kislinger T, Pachydaki SI, Jenkins DG, Weinberg A, Lefkowitch J, Rogiers X, Yan SF, Schmidt AM, Emond JC. RAGE limits regeneration after massive liver injury by coordinated suppression of TNFalpha and NF-kappaB. J Exp Med 2005; 201: 473-484 [PMID: 15699076 DOI: 10.1084/jem.20040934]
98. Goodwin M, Herath C, Jia Z, Leung C, Coughlan MT, Forbes J, Angus P. Advanced glycation end products augment experimental hepatic fibrosis. J Gastroenterol Hepatol 2013; 28: 369-376 [PMID: 23173780 DOI: 10.1111/jgh.12042]
99. Lohwasser C, Neureiter D, Popov Y, Bauer M, Schuppan D. Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol 2009; 15: 5789-5798 [PMID: 19998499 DOI: 10.3748/wjg.15.5789]
100. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 1049-1055 [PMID: 14642625]
101. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 2005; 51: 1749-1750 [PMID: 16120960]
102. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007; 23: 368-371 [PMID: 17024691]
103. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49: 2756-2762 [PMID: 16969649]
104. Nakamura K, Yamagishi SI, Matsui T, Adachi H, Takeuchi M, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 2007; 7: 188-190 [PMID: 18188534 DOI: 10.1007/ s10238-007-0146-7]
105. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006; 55: 1227-1231 [PMID: 16919543]
106. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Imaizumi T. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007; 13: 185-189 [PMID: 17592553 DOI: 10.2119/2006-00090.Nakamura]
107. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita- Nakamura Y, Takeuchi M, Inoue H, Imaizumi T. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24: 109-114 [PMID: 17694504]
108. Yamagishi S, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol 2007; 27: e32; author reply e33-e34 [PMID: 17522392]
109. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007; 8: 1138-1143 [PMID: 17979674]
110. Yoshida T, Yamagishi S, Matsui T, Nakamura K, Ueno T, Takeuchi M, Sata M. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2008; 36: 237-243 [PMID: 18380932]
111. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPARgamma)- modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-469 [PMID: 17691961]
112. Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, Hombach V, de Caterina R, Basta G, Wautier MP, Wautiers JL. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53: 2662-2668 [PMID: 15448098]
113. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Makino T, Shimizu T, Sata M. Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive expression in hepatoma cells by suppressing reactive oxygen species generation. Vascular Dis Prevent 2007; 4: 213-216
114. Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-757 [PMID: 20112031 DOI: 10.1007/s00535-010-0203-y]
115. Vilà L, Rebollo A, Adalsteisson GS, Alegret M, Merlos M, Roglans N, Laguna JC. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol 2011; 251: 32-40 [PMID: 21122807 DOI: 10.1016/j.taap.2010.11.011]
116. Patel R, Baker SS, Liu W, Desai S, Alkhouri R, Kozielski R, Mastrandrea L, Sarfraz A, Cai W, Vlassara H, Patel MS, Baker RD, Zhu L. Effect of dietary advanced glycation end products on mouse liver. PLoS One 2012; 7: e35143 [PMID: 22496902 DOI: 10.1371/journal.pone.0035143]
117. Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, Forbes JM, Angus PW. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol 2014; 60: 832-838 [PMID: 24316518 DOI: 10.1016/j.jhep.2013.11.033]
118. Sato T, Wu X, Shimogaito N, Takino J, Yamagishi S, Takeuchi M. Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys. Eur J Nutr 2009; 48: 6-11 [PMID: 19083041 DOI: 10.1007/s00394-008-0753-4]
119. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997; 62: S23-S28 [PMID: 9350673]
120. Ueda S, Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, Kaneyuki U, Fujimura T, Hayashida A, Okuda S. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 2006; 12: 180-184 [PMID: 17088950 DOI: 10.2119/2005-00034]
121. Choei H, Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, Kikuchi S, Saito T. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol 2004; 108: 189-193 [PMID: 15221334]
122. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2006; 21: 197-208 [PMID: 16869341]
123. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008; 14: 973-978 [PMID: 18473848]
124. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008; 14: 940-945 [PMID: 18473843]
125. Sakuraoka Y, Sawada T, Okada T, Shiraki T, Miura Y, Hiraishi K, Ohsawa T, Adachi M, Takino J, Takeuchi M, Kubota K. MK615 decreases RAGE expression and inhibits TAGEinduced proliferation in hepatocellular carcinoma cells. World J Gastroenterol 2010; 16: 5334-5341 [PMID: 21072897 DOI: 10.3748/wjg.v16.i42.5334]
126. Takino J, Yamagishi S, Takeuchi M. Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol 2012; 18: 1781-1788 [PMID: 22553402 DOI: 10.3748/wjg.v18.i15.1781]
127. Kan H, Yamagishi SI, Ojima A, Fukami K, Ueda S, Takeuchi M, Hyogo H, Aikata H, Chayama K. Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma. J Clin Lab Anal 2014; Epub ahead of print [PMID: 25252033]